E
3.22
-0.37 (-10.31%)
| Penutupan Terdahulu | 3.59 |
| Buka | 3.53 |
| Jumlah Dagangan | 844,243 |
| Purata Dagangan (3B) | 471,546 |
| Modal Pasaran | 72,975,184 |
| Harga / Jualan (P/S) | 1.15 |
| Harga / Buku (P/B) | 4.51 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Mar 2026 |
| Margin Keuntungan | -27.34% |
| Margin Operasi (TTM) | -21.71% |
| EPS Cair (TTM) | -0.840 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 7.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 367.92% |
| Nisbah Semasa (MRQ) | 2.32 |
| Aliran Tunai Operasi (OCF TTM) | -14.91 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.11 M |
| Pulangan Atas Aset (ROA TTM) | -19.21% |
| Pulangan Atas Ekuiti (ROE TTM) | -117.50% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Exagen Inc. | Menurun | Menaik |
AISkor Stockmoo
1.3
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | -0.5 |
| Purata | 1.30 |
|
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 19.82% |
| % Dimiliki oleh Institusi | 45.44% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 10.00 (BTIG, 210.56%) | Beli |
| 10.00 (TD Cowen, 210.56%) | Beli | |
| Median | 10.00 (210.56%) | |
| Rendah | 8.00 (B. Riley Securities, 148.45%) | Beli |
| Purata | 9.33 (189.75%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 3.56 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| TD Cowen | 24 Feb 2026 | 10.00 (210.56%) | Beli | 3.69 |
| BTIG | 17 Feb 2026 | 10.00 (210.56%) | Beli | 3.31 |
| B. Riley Securities | 30 Jan 2026 | 8.00 (148.45%) | Beli | 3.68 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| ABALLI JOHN | - | 3.69 | -11,430 | -42,177 |
| BLACK JEFFREY G. | - | 3.69 | -1,584 | -5,845 |
| Jumlah Keseluruhan Kuantiti Bersih | -13,014 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -48,022 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 3.69 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| BLACK JEFFREY G. | Pegawai | 24 Feb 2026 | Jual (-) | 1,584 | 3.69 | 5,845 |
| ABALLI JOHN | Pegawai | 24 Feb 2026 | Jual (-) | 11,430 | 3.69 | 42,177 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 11 Jan 2026 | Pengumuman | Exagen Inc. Announces Select Preliminary 2025 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |